ALT Similar Chart Price Prediction
The price of ALT is predicted to go up 5.17%, based on the high correlation periods with AIT. The similarity of these two price pattern on the periods is 92.88%.
ALT
AIT
Up: 5.17%Similarity: 92.88%
ALT Revenue Forecast
ALT EPS Forecast
ALT FAQs
What is bull’s view on ALT?
What is bear's view on ALT?
What is ALT revenue forecast for next quarter？
ALT Analyst's Forecast
Annabel Samimy
Stifel
Strong Buy
2025-01-08
Price Target
$18
Upside
+140.48%
Stifel analyst Annabel Samimy initiated coverage of Altimmune with a Buy rating and $18 price target. The company is developing next-generation peptide-based therapeutics with a novel GLP-1/glucagon dual agonist targeting the nexus of metabolic disease, obesity and dyslipidemia, and the firm contends that the next chapters in metabolic disease treatment will require innovation beyond the diabetes-obesity connection to address the numerous other related comorbidities of obesity, the analyst tells investors in a research note. Altimmune's lead asset, pemvidutide/ALT-801, falls squarely in that trend, combining the potent weight-loss effects of GLP-1 with glucagon's direct liver-targeted lipid metabolism, the firm adds.
Eliana Merle
UBS
Strong Buy
2024-11-12
Price Target
$26
Upside
+176.16%
